Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235027 | 0.86 | MAOB (0.43) | MEN1KMT2AMAOBADORA2AADORA2B | |
| SCHEMBL1201682 | 0.85 | MAPK8 (0.40) | MAPK8MAPK9MAPK10CA1CA2 | |
| SCHEMBL1201420 | 0.83 | NAMPT (0.44) | MEN1KMT2AMAPK8MAPK9MAPK10 | |
| SCHEMBL4242624 | 0.81 | DHODH (0.52) | KDM4ECNR2MAOBADORA2AADORA2B | |
| SCHEMBL4239506 | 0.81 | PRKDC (0.43) | MEN1KMT2ACNR2MAOBADORA2A | |
| SCHEMBL8260877 | 0.81 | MAOB (0.49) | MEN1KMT2ACNR2MAOBADORA2A | |
| SCHEMBL1202270 | 0.80 | PARP1 (0.38) | KDM4EMEN1POLBKMT2AMAOB | |
| SCHEMBL12846013 | 0.78 | MAOB (0.47) | MEN1KMT2ACNR2MAOBADORA2A | |
| SCHEMBL9611650 | 0.78 | RIPK1 (0.52) | CNR2MAOBADORA2AADORA2BADORA1 | |
| SCHEMBL4239542 | 0.77 | CYP2C9 (0.49) | KDM4EMAPK8MAPK9MAPK10NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | KDM4E 3510/4885MEN1 2918/4885POLB 972/4885 |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | BACE1, BACE2, APP | KDM4E 3536/4885MEN1 3092/4885POLB 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.